Madison Wealth Management Trims Stake in Johnson & Johnson (NYSE:JNJ)

Madison Wealth Management trimmed its position in Johnson & Johnson (NYSE:JNJFree Report) by 1.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,522 shares of the company’s stock after selling 243 shares during the period. Madison Wealth Management’s holdings in Johnson & Johnson were worth $2,729,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. ABLE Financial Group LLC lifted its stake in shares of Johnson & Johnson by 11.2% during the third quarter. ABLE Financial Group LLC now owns 7,259 shares of the company’s stock worth $1,131,000 after buying an additional 733 shares during the period. Vaughan David Investments LLC IL lifted its stake in shares of Johnson & Johnson by 1.0% during the third quarter. Vaughan David Investments LLC IL now owns 299,133 shares of the company’s stock worth $46,590,000 after buying an additional 3,048 shares during the period. Qsemble Capital Management LP acquired a new stake in shares of Johnson & Johnson during the third quarter worth $2,585,000. Harbor Advisors LLC acquired a new stake in shares of Johnson & Johnson during the third quarter worth $359,000. Finally, AWM Capital LLC lifted its stake in shares of Johnson & Johnson by 4.6% during the third quarter. AWM Capital LLC now owns 2,843 shares of the company’s stock worth $443,000 after buying an additional 124 shares during the period. 68.40% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. UBS Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their target price for the stock from $167.00 to $180.00 in a report on Friday, December 1st. TheStreet cut shares of Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, November 17th. Morgan Stanley reduced their target price on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a report on Wednesday, January 24th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, January 24th. Eight equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $176.14.

Read Our Latest Report on JNJ

Johnson & Johnson Stock Up 0.2 %

JNJ stock opened at $156.76 on Friday. The stock has a market capitalization of $377.37 billion, a P/E ratio of 11.35, a P/E/G ratio of 2.63 and a beta of 0.53. The firm has a 50-day simple moving average of $158.20 and a 200-day simple moving average of $158.83. The company has a quick ratio of 0.96, a current ratio of 1.21 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 52 week low of $144.95 and a 52 week high of $175.97.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its earnings results on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. The business had revenue of $21.40 billion during the quarter, compared to analysts’ expectations of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 36.75%. The company’s quarterly revenue was down 9.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.35 earnings per share. Equities analysts forecast that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 5th. Stockholders of record on Tuesday, February 20th will be paid a dividend of $1.19 per share. The ex-dividend date of this dividend is Friday, February 16th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.04%. Johnson & Johnson’s dividend payout ratio is currently 34.47%.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.